dr. goldberg discusses osimertinib in nsclc
Published 6 years ago • 88 plays • Length 1:52Download video MP4
Download video MP3
Similar videos
-
2:00
dr. goldberg on sequencing following treatment with osimertinib in nsclc
-
1:16
dr. goldberg on options after developing resistance to osimertinib for nsclc
-
1:41
dr. goldberg on resistance to osimertinib for nsclc
-
1:31
dr. gold on the future of osimertinib in lung cancer
-
2:02
dr. goldberg discusses resistance to egfr tki therapy in nsclc
-
1:47
dr. goldberg on further immunotherapy trials in non-small cell lung cancer
-
0:42
dr. fidler discusses osimertinib in egfr-mutated lung cancer
-
7:45
upfront use of osimertinib in egfr nsclc
-
1:41
dr. goldberg on pd-l1 as a biomarker in lung cancer
-
3:17
osimertinib in egfr-positive nsclc with brain metastases
-
2:05
dr. garassino discusses promising findings with osimertinib for patients with nsclc and brain mets
-
0:50
targeted option for non-small cell lung cancer #2023 #oncology #lungcancer
-
6:51
osimertinib as frontline therapy in egfr-positive nsclc
-
2:04
acquired resistance to osimertinib in t790m-positive nsclc
-
1:57
dr. wakelee on benefits of osimertinib in egfr-mutant nsclc treatment
-
1:09
sarah b. goldberg discusses new immunotherapy options for patients with lung cancer
-
1:33
dr. yang on resistance mechanisms from osimertinib in nsclc
-
1:06
dr. shum on patient consultation of osimertinib in nsclc
-
2:11
dr. low on osimertinib versus dacomitinib in egfr-mutant nsclc